SIREN : 448798983
IMMUNIA is a French company founded 22 years ago, specialized in the sector Travaux d'étanchéification. Based in LES ALLUETS-LE-ROI (78580), this company of category PME shows in 2025 a revenue of 1.3 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1 254 802 € | 1 332 850 € | 1 508 476 € | 1 371 893 € | 1 268 450 € | 1 263 045 € | 1 179 687 € | 1 091 100 € | 988 960 € |
| Net income | 37 207 € | 70 548 € | 29 975 € | 27 880 € | 35 105 € | 36 079 € | 22 672 € | 58 855 € | 29 023 € |
| EBITDA | 34 625 € | 133 746 € | 14 812 € | 118 364 € | 87 544 € | 71 072 € | 45 487 € | 82 290 € | 58 012 € |
| Net margin | 3.0% | 5.3% | 2.0% | 2.0% | 2.8% | 2.9% | 1.9% | 5.4% | 2.9% |
In 2025, IMMUNIA achieves revenue of 1.3 M€. Revenue is growing positively over 9 years (CAGR: +3.0%). Slight decline of -6% vs 2024. After deducting consumption (413 k€), gross margin stands at 842 k€, i.e. a rate of 67%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 35 k€, representing 2.8% of revenue. Warning negative scissor effect: despite revenue change (-6%), EBITDA varies by -74%, reducing margin by 7.3 pts. This reflects costs rising faster than revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 37 k€, i.e. 3.0% of revenue. This profit can be retained or distributed to shareholders.
1 254 802 €
842 063 €
34 625 €
41 413 €
37 207 €
2.8%
The debt ratio (= Financial debt / Equity x 100) stands at 27%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 39%. The balance between equity and debt is satisfactory. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 1.9 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 2.1% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.
26.99%
39.057%
2.107%
1.894
15.4%
In 2025, the debt ratio of IMMUNIA (26.99) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2025, the financial autonomy of IMMUNIA (39.1%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2025, the repayment capacity of IMMUNIA (1.89) ranks in the top 25% of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A long duration may signal heavy debt relative to repayment capacity.
The liquidity ratio (= Current assets / Current liabilities) stands at 165.13. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 1.6x. Coverage is limited: any activity downturn would jeopardize interest payments.
165.132
1.58
In 2025, the liquidity ratio of IMMUNIA (165.13) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2025, the interest coverage of IMMUNIA (1.6x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 68 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 78 days. Favorable situation: supplier credit is longer than customer credit by 10 days. Inventory turnover is 7 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 87 days of revenue, i.e. 304 k€ to permanently finance.
303 562 €
68 j
78 j
7 j
87 j
Indicative estimate only : the number of comparable transactions in this sector is limited (22 transactions). This range of 74 438€ to 291 200€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 22 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare IMMUNIA with other companies in the same sector:
Voir toutes les statistiques du secteur Travaux d'étanchéification
The revenue of IMMUNIA in 2025 is 1.3 M€.
Yes, IMMUNIA generated a net profit of 37 k€ in 2025.
The headquarters of IMMUNIA is located in LES ALLUETS-LE-ROI (78580), in the department Yvelines.
The tax return of IMMUNIA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
IMMUNIA operates in the sector Travaux d'étanchéification (NAF code 43.99A). See the 'Sector positioning' section above to compare the company with its competitors.